Published in Cancer Detection and Prevention 1993; 17(1).

The genetic origin of the cancer recognition, immunedefense suppression and serine protease protection (CRISPP) peptide

Cercek PhD, L., Siaw PhD, M., Cercek PhD, B., Cercek, B.

Beckman Instruments Inc,, Brea, CA 92621, USA.

The results of a two-antibody immunoassay, designed to distinguish between the ALPHA1-protease inhibitor (ALPHA1-PI) and the partially homologous low molecular weight CRISPP peptides produced by cancer calls, indicated that CRISPP peptides are not a degradation product of ALPHA1-PI. The CRISPP/ALPHA1-PI ratios in cultured malignant versus the normal cell counterparts are 3.5-times higher than would be expected if the CRISPP peptides were an enzymatic breakdown product of ALPHA1-PI. The possible existence of a mRNA and DNA coding for the CRISPP peptides was investigated by quantitative dot blot DNA probe hybridization. The results show that the mRNA and DNA signal ratios of CRISPP/ALPHA1-PI probes are up to 3-times and 6-times greater, respectively, in malignant cells than in their normal cell counterparts, This suggests that the CRISPP peptide could be a product of inherited or acquired inheritable carcinogenic damage to the ALPHA1-PI gene DNA.

Paper presented at the International Symposium on Genetic Factors in Predictive and Preventive Oncology; Nice, France; March 14-16, 1993; in the section on Prognostic Indicators.